Erasca, Inc. (ERAS) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है San Diego, CA, United States. वर्तमान CEO हैं Jonathan E. Lim.
ERAS के पास है IPO तिथि 2021-07-16, 103 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $5.55B.
Erasca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancers driven by RAS/MAPK pathway alterations. The company's lead program, ERAS-007, is an oral ERK1/2 inhibitor in development for non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia, while ERAS-601, an oral SHP2 inhibitor, targets advanced and metastatic solid tumors. Erasca is also advancing ERAS-801, a CNS-penetrant EGFR inhibitor designed to treat recurrent glioblastoma multiforme. Founded in 2018 and headquartered in San Diego, California, the company aims to address significant unmet needs in oncology through precision-targeted drug development.
